The content on this site is intended for healthcare professionals only
Dr Andrew Epstein, Prof Richard Schilsky and Dr Geertjan van Tienhoven comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from the PREOPANC-1 trial.
This was a phase III randomised trial in which patients with resectable pancreatic cancer received 10 weeks of chemoradiotherapy prior to surgery, or immediate surgery alone.
For more on these results, watch Dr van Tienhoven present this data in a press conference here, watch Dr van Tienhovens interview with ecancer here, or read news coverage here.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
Adjuvant radiotherapy has no benefit following radical prostatectomy
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 25th - 31st, 2023
OncoAlert Round Up for August 4th - 10th, 2023
